波立维说明书及用量用法
波立维药物说明书
波立维药物说明书精品文档波立维药物说明书波立维是用于治疗脑血管类的药物,有效成分主要适应于心肌梗死,下面是整理的波立维说明书,希望对有所帮助。
波立维商品介绍波立维通用名,硫酸氢氯吡格雷片生产厂家: 赛诺菲(杭州)制药有限公司批准文号,国药准字J20080090药品规格,75mg*7片价格,,2 起波立维说明书【商品名称】波立维【通用名称】硫酸氢氯吡格雷片【英文名称】Clopidogrel Hydrogen Sulphate Tablets【汉语拼音】LiuSuanQingLvBiGeLeiPian【主要成分】硫酸氢氯吡格雷【性状】75mg薄膜衣片剂呈粉红色,园形双凸,薄膜包衣,一面刻有《75》,一面刻有《7》字样。
【适应症】氯吡格雷用于以下患者的预防动脉粥样硬化血栓形成事件,、心肌梗死患者(从几天到小于35天)、缺血性卒中患者(从7天到小于6个月)或确诊外周动脉性疾病的患者。
、急性冠脉综合症的患者。
1 / 12精品文档、非ST段抬高性急性冠脉综合症(包括不稳定性心绞痛或非Q波心肌梗死),包括经皮冠状动脉介入术后置入支架的患者与阿司匹林合用。
、用于ST段抬高性急性冠脉综合症患者,与阿司匹林联合,可合并在溶栓治疗中使用。
【用法用量】推荐剂量为每天75mg,与或不与食物同服,对于老年患者不需调整剂量。
对于急性冠脉综合症的患者,、非ST段抬高性急性冠脉综合症(不稳定性心绞痛或非Q波心肌梗死)患者,应以单次负荷量氯吡格雷300mg开始,然后以75mg每日次连续服药(合用阿司匹林75mg-325mg/日)。
由于服用较高剂量的阿司匹林有较高的出血危险性,故推荐阿司匹林的剂量不应超过00mg。
好疗程尚未正式确定。
临床试验资料支持用药2个月,用药3个月后表现出大效果。
、ST段抬高性急性心肌梗死,应以负荷量氯吡格雷开始,然后以75mg每日次,合用阿司匹林,可合用或不合用溶栓剂。
对于年龄超过75岁的患者,不使用氯吡格雷负荷剂量。
硫酸氢氯吡格雷片(波立维)国外说明书
核准日期：硫酸氢氯吡格雷片说明书请仔细阅读说明书并在医师指导下使用【药品名称】通用名：硫酸氢氯吡格雷片英文名：Clopidogrel Hyd rogen Sulphate Tablets汉语拼音：Liusuanqinglubigelei Pian本品主要成份为：硫酸氢氯吡格雷化学名称为：：甲基(+)-(s)-α-邻氯苯基-6，7-二氢噻吩[3，2-C]吡啶-5(4H)-乙酸酯硫酸氢盐，其结构式为：分子式：C16H16ClNO2S·H2SO4分子量：419.9【性状】硫酸氢氯吡格雷片75mg 薄膜衣片剂呈粉红色，圆形双凸，薄膜包衣，一面刻有《75》，另一面刻有《1171》字样。
【适应症】氯吡咯雷用于以下患者的预防动脉粥样硬化血栓形成事件：·心肌梗死患者（从几天到小于35 天）、缺血性卒中患者（从7 天到小于6 个月）或确诊外周动脉性疾病的患者。
·急性冠脉综合征的患者-非ST 段抬高性急性冠脉综合征（包括不稳定性心绞痛或非Q波心肌梗死），包括经皮冠状动脉介入术后置入支架的患者，与阿司匹林合用。
-用于ST 段抬高性急性冠脉综合征患者，与阿司匹林联合，可合并在溶栓治疗中使用。
【规格】75 mg【用法用量】成人和老年人硫酸氢氯吡格雷片的推荐剂量为每天75mg，与或不与食物同服。
对于急性冠脉综合征的患者：-非ST 段抬高性急性冠脉综合征（不稳定性心绞痛或非Q波心肌梗死）患者，应以单次负荷量氯吡格雷300 mg开始，然后以75 mg每日1 次连续服药（合用阿司匹林75 mg-325 mg/日）。
由于服用较高剂量的阿司匹林有较高的出血危险性，故推荐阿司匹林的剂量不应超过100 mg。
最佳疗程尚未正式确定。
临床试验资料支持用药12个月，用药3个月后表现出最大效果。
-ST段抬高性急性心肌梗死：应以负荷量氯吡格雷开始，然后以75 mg每日1次，合用阿司匹林，可合用或不合用溶栓剂。
对于年龄超过75岁的患者，不使用氯吡格雷负荷剂量。
【免费下载】波立维的药品说明书全
如果漏服：
一在常规服药时间的 12 小时内漏服：患者应立即补服一次标准剂量，并按照常规服药时间服用下 一次剂量：
超过常规服药时间 12 小时后漏服：患者应在下次常规服药时间服用标准剂量，无需剂量加倍。
急性冠脉综合征的患者 1. 非 ST 段抬高性急性冠脉综合征（包括不稳定性心绞痛或非 Q 波心肌梗死），包括 经皮冠状动脉介入术后置入支架的患者，与阿司匹林合用。 2. 用于 ST 段抬高性急性冠脉综合征患者，与阿司匹林联合，可合并在溶栓治疗中使 用。
75mg
成人和老年人
氯毗格雷的推荐剂量为 75mg 每日一次。
儿童和未成年人：
对全部高中资料试卷电气设备，在安装过程中以及安装结束后进行高中资料试卷调整试验；通电检查所有设备高中资料电试力卷保相护互装作置用调与试相技互术关，系电，力根通保据过护生管高产线中工敷资艺设料高技试中术卷资，配料不置试仅技卷可术要以是求解指，决机对吊组电顶在气层进设配行备置继进不电行规保空范护载高与中带资负料荷试下卷高问总中题体资，配料而置试且时卷可，调保需控障要试各在验类最；管大对路限设习度备题内进到来行位确调。保整在机使管组其路高在敷中正设资常过料工程试况中卷下，安与要全过加，度强并工看且作护尽下关可都于能可管地以路缩正高小常中故工资障作料高；试中对卷资于连料继接试电管卷保口破护处坏进理范行高围整中，核资或对料者定试对值卷某，弯些审扁异核度常与固高校定中对盒资图位料纸置试，.卷保编工护写况层复进防杂行腐设自跨备动接与处地装理线置，弯高尤曲中其半资要径料避标试免高卷错等调误，试高要方中求案资技，料术编试交写5、卷底重电保。要气护管设设装线备备置敷4高、调动设中电试作技资气高，术料课中并3中试、件资且包卷管中料拒含试路调试绝线验敷试卷动槽方设技作、案技术，管以术来架及避等系免多统不项启必方动要式方高，案中为；资解对料决整试高套卷中启突语动然文过停电程机气中。课高因件中此中资，管料电壁试力薄卷高、电中接气资口设料不备试严进卷等行保问调护题试装，工置合作调理并试利且技用进术管行，线过要敷关求设运电技行力术高保。中护线资装缆料置敷试做设卷到原技准则术确：指灵在导活分。。线对对盒于于处调差，试动当过保不程护同中装电高置压中高回资中路料资交试料叉卷试时技卷，术调应问试采题技用，术金作是属为指隔调发板试电进人机行员一隔，变开需压处要器理在组；事在同前发一掌生线握内槽图部内 纸故，资障强料时电、，回设需路备要须制进同造行时厂外切家部断出电习具源题高高电中中源资资，料料线试试缆卷卷敷试切设验除完报从毕告而，与采要相用进关高行技中检术资查资料和料试检，卷测并主处且要理了保。解护现装场置设。备高中资料试卷布置情况与有关高中资料试卷电气系统接线等情况，然后根据规范与规程规定，制定设备调试高中资料试卷方案。
波立维说明书
药品商品名称波立维药品正式名称硫酸氢氯吡格雷药品英文名称Plavix药品规格75mg*7粒/盒基本药理血小板聚集抑制剂，通过选择性抑制二磷酸腺苷（ADP）与血小板结合及继发由ADP介导的糖蛋白复合物活化。
临床用途适用于有过近期发作的中风、心肌梗塞和确诊外周动脉硬化的患者，波立维（氯吡格雷）可减少动脉粥样硬化性事件的发生（如心肌梗塞，中风和血管性死亡）。
给药途径及用量推荐剂量每日75mg，对老年患者和肾病患者不需调整剂量[用法用量]：推荐剂量为每天75mg，与或不与食物同服。
对于老年患者和肾病患者不需调整剂量。
[不良反应]：出血，波立维（氯吡格雷）严重出血事件的发生率分别为1.4% 胃肠道：如腹痛，消化不良，胃炎和便秘皮疹和其它皮肤病中枢和周围神经系统：头痛、眩晕、头昏和感觉异常肝脏和胆道疾病禁忌证对药品或本品任一成分过敏严重的肝脏损伤活动性病理性出血，如消化性溃疡或颅内出血注意事项：氯吡格雷延长出血时间，对于有伤口（特别是在胃肠道和眼内）易出血的病人应慎用。
病人应知服用波立维止血时间可能比往常长，同时病人应向医生报告异常出血情况，手术前和服用其它新药前病人应告知医生他们在服用波立维。
由于患有肾脏损伤病人使用氯吡格雷的经验极有限，因此这些病人应慎用波立维（氯吡格雷）。
严重肝病的病人可能有出血倾向，这类病人使用本药的经验极有限，应慎用波立维。
由于服用华法令也有出血倾向，所以服用时不推荐同时使用华法令。
对于同时服用易出现胃肠道伤口的药物（如非甾体消炎药）的病人应慎用波立维未见服用本药后对驾驶或心理学检测产生影响不建议孕妇及哺乳期妇女服用此药。
在儿科使用的安全性和有效性还未明确。
我有一位家属患有“冠心病”伴高血压，去年做了支架手术，现在常期靠药物来维持，当然也包括波立维，不过波立维的价钱挺贵的，一般都要20多块钱一颗。
【批准文号】国药准字H20056410【中文名称】硫酸氢氯吡格雷片【产品英文名称】Clopidogrel Sulfate Tablets【生产企业】杭州赛诺菲安万特民生制药有限公司【功效主治】预防和治疗因血小板高聚集状态引起的心、脑及其它动脉的循环障碍疾病。
波立维硫酸氢氯吡格雷片使用说明
波立维硫酸氢氯吡格雷片【品牌】波立维：【用法用量】成人和老年人：通常推荐成人75mg1日1次口服给药，但根据年龄、体重、症状可50mg1日1次口服给药，与或不与食物同服。
对于急性冠脉综合征的患者：-非ST段抬高性急性冠脉综合征（不稳定性心绞痛或非Q波心肌梗死）患者，应以单次负荷量氯吡格雷300mg开始，然后以75mg每日1次连续服药（合用阿司匹林75mg-325mg/日）。
由于服用较高剂量的阿司匹林有较高的出血危险性，故推荐阿司匹林的剂量不应超过100mg。
最佳疗程尚未正式确定。
临床试验资料支持用药12个月，用药3个月后表现出最大效果。
-ST段抬高性急性心肌梗死：应以单次负荷量氯吡格雷300mg开始，然后以75mg每日1次，合用阿司匹林，可合用或不合用溶栓剂。
对于年龄超过75岁的患者，不使用氯吡格雷负荷剂量。
在症状出现后应尽早开始联合治疗，并至少用药4周。
目前还没有研究对联合使用氯吡格雷和阿司匹林超过4周后的获益进行确证。
儿童和未成年人：尚无在儿童中使用的经验。
【注意事项】1.由于出血和血液学不良反应的危险性，在治疗过程中一旦出现出血的临床症状，就应立即考虑进行血细胞计数和/或其它适当的检查。
2.与其它抗血小板药物一样，因创伤﹑外科手术或其它病理状态使出血危险性增加的病人和接受阿司匹林﹑非甾体抗炎药﹑肝素﹑血小板糖蛋白IIb/IIIa（GPIIb/IIIa）拮抗剂或溶栓药物治疗病人应慎用氯吡格雷，病人应密切随访，注意出血包括隐性出血的任何体征，特别是在治疗的最初几周和或心脏介入治疗﹑外科手术之后。
因可能使出血加重，不推荐氯吡格雷与华法林合用。
（参见【药物相互作用】）。
3.在需要进行择期手术的患者，如抗血小板治疗并非必须，则应在术前停用氯吡格雷7天以上。
氯吡格雷延长出血时间，患有出血性疾病（特别是胃肠﹑眼内疾病）的患者慎用。
应告诉患者，当他们服用氯吡格雷（单用或与阿司匹林合用）时止血时间可能比往常长，同时病人应向医生报告异常出血情况（部位和出血时间）。
波立维说明书
波立维说明书
一、波立维说明书二、波立维的用法用量三、波立维的注意事项
波立维说明书1、波立维的功能主治
氯吡格雷用于以下患者的预防动脉粥样硬化血栓形成事件; --心肌梗死患者(从几天到小于35天)、缺血性卒中患者(从7天到小于6个月)或确诊外周动脉性疾病的患者。
--急性冠脉综合症的患者 -非ST段抬高性急性冠脉综合症(包括不稳定性心绞痛或非Q波心肌梗死),包括经皮冠状动脉介入术后置入支架的患者与阿司匹林合用。
-用于ST段抬高性急性冠脉综合症患者,与阿司匹林联合,可合并在溶栓治疗中使用。
2、波立维的禁忌
2.1、对药品或本品任一成份过敏。
2.2、严重的肝脏损伤。
2.3、活动性病理性出血,如消化性溃疡或颅内出血。
2.4、哺乳(参见妊娠和哺乳)。
3、波立维的药物相互作用
阿斯匹林:本品增加阿斯匹林对胶原引起的血小板聚集的抑制效果,长期合并用药的安全性无进一步的研究资料。
肝素:健康志愿者研究表明,本品与肝素无相互作用。
但合并用药时应小心。
非甾体抗炎药(NSAIDs):健康志愿者同时服用本品和萘普生,胃肠潜血损失增加,故本品与NSAIDs合用时应小心。
法华令:无合并用药的安全性研究。
4、波立维的药理作用。
波立维的功能主治是什么意思
波立维的功能主治是什么意思什么是波立维？波立维（Boterwee）是一种常见的中成药，属于消化系统药物类别。
它由多种天然草药制成，并被广泛用于治疗消化系统相关疾病。
波立维具有多种功能和主治，下面将详细介绍。
功能主治波立维主要用于以下疾病的治疗：1.胃动力障碍：波立维可刺激胃肠道平滑肌收缩，促进胃肠蠕动，帮助消化食物。
它可用于治疗胃排空障碍、胃胀等症状，改善消化。
2.消化不良：波立维具有增加胃酸分泌功能，可以帮助消化，促进食物的吸收和代谢。
常见的消化不良症状包括胃胀、食欲不振、消化不良等。
3.胃酸逆流：波立维具有减少胃酸逆流的能力，能够缓解胃酸对食道的刺激。
因此，它被广泛应用于治疗胃食管逆流病（GERD）等相关疾病。
4.胃溃疡：波立维对胃粘膜有保护作用，可以减少胃液对胃壁的损伤。
它常被用于治疗胃溃疡、十二指肠溃疡等胃肠溃疡病。
5.膳食过敏：波立维还具有一定的抗过敏作用，可以减轻或缓解食物过敏引起的不适症状。
使用方法波立维常见的用法和用量如下：•平均剂量：成人一次2片，一日3次。
儿童一次半片，一日3次。
•用量和用法应根据医生的指导或根据说明书中的说明进行。
注意事项在使用波立维前，应注意以下事项：1.应遵医嘱使用，根据病情和医生指导确定用量和疗程。
2.孕妇、哺乳期妇女和儿童应在医生指导下使用。
3.对波立维过敏者禁用，过敏体质者使用时应慎重。
4.使用过程中如出现不良反应，应及时停药并咨询医生。
常见不良反应使用波立维可能会引起一些不良反应，常见的不良反应包括：1.胃肠道不适：常见的不良反应包括恶心、呕吐、腹泻、便秘等。
2.过敏反应：少数患者可能会出现皮疹、荨麻疹、瘙痒等过敏症状。
3.头晕、头痛等轻度反应。
如出现上述不良反应或其他不适，应立即停药并就医。
结论波立维是一种常见的中成药，主要用于消化系统相关疾病的治疗。
它通过促进胃肠蠕动、增加胃酸分泌、减少胃酸逆流等作用，改善消化不良、胃动力障碍等症状。
使用时需要谨慎遵医嘱，注意用量和疗程，避免不良反应的发生。
硫酸氢氯吡格雷片说明书(美国,FDA,英文)
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to usePLAVIX safely and effectively. See full prescribing information forPLAVIX.PLAVIX (clopidogrel bisulfate) tabletsInitial U.S. Approval: 1997WARNING: DIMINISHED EFFECTIVENESS IN POORMETABOLIZERSSee full prescribing information for complete boxed warning.• Effectiveness of Plavix depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1)• Poor metabolizers treated with Plavix at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome(ACS) or percutaneous coronary intervention (PCI) than patients withnormal CYP2C19 function. (12.5)• Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5)• Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.1)----------------------------RECENT MAJOR CHANGES--------------------------BoxedWarning 03/2010 Dosage and Administration (2.3, 2.4) 08/2010 Warnings and Precautions (5.1, 5.2, 5.3) 08/2010----------------------------INDICATIONS AND USAGE---------------------------Plavix is a P2Y12 platelet inhibitor indicated for:• Acute coronary syndrome- For patients with non-ST-segment elevation ACS [unstable angina(UA)/non-ST-elevation myocardial infarction (NSTEMI)] includingpatients who are to be managed medically and those who are to bemanaged with coronary revascularization, Plavix has been shown todecrease the rate of a combined endpoint of cardiovascular death,myocardial infarction (MI), or stroke as well as the rate of a combinedendpoint of cardiovascular death, MI, stroke, or refractory ischemia.(1.1)- For patients with ST-elevation myocardial infarction (STEMI), Plavixhas been shown to reduce the rate of death from any cause and the rateof a combined endpoint of death, re-infarction, or stroke. The benefitfor patients who undergo primary PCI is unknown. (1.1)• Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint ofnew ischemic stroke (fatal or not), new MI (fatal or not), and othervascular death. (1.2)----------------------DOSAGE AND ADMINISTRATION----------------------• Acute coronary syndrome (2.1)- Non-ST-segment elevation ACS (UA/NSTEMI): 300 mg loading dosefollowed by 75 mg once daily, in combination with aspirin(75-325 mg once daily)- STEMI: 75 mg once daily, in combination with aspirin (75-325 mgonce daily), with or without a loading dose and with or withoutthrombolytics• Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily (2.2)---------------------DOSAGE FORMS AND STRENGTHS---------------------Tablets: 75 mg, 300 mg (3)-------------------------------CONTRAINDICATIONS-----------------------------• Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage (4.1)• Hypersensitivity to clopidogrel or any component of the product (4.2)-----------------------WARNINGS AND PRECAUTIONS------------------------ • Reduced effectiveness in impaired CYP2C19 function: Avoid concomitant use with drugs that are strong or moderate CYP2C19 inhibitors (e.g.,omeprazole). (5.1)• Bleeding: Plavix increases risk of bleeding. Discontinue 5 days prior to elective surgery. (5.2)• Discontinuation of Plavix: Premature discontinuation increases risk of cardiovascular events. (5.3)• Recent transient ischemic attack or stroke: Combination use of Plavix and aspirin in these patients was not shown to be more effective than Plavix alone, but was shown to increase major bleeding. (5.4)• Thrombotic thrombocytopenic purpura (TTP): TTP has been reported with Plavix, including fatal cases. (5.5)------------------------------ADVERSE REACTIONS------------------------------Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership at 1-800-633-1610 or FDA at 1-800-FDA-1088 or /medwatch.------------------------------DRUG INTERACTIONS-------------------------------• Nonsteroidal anti-inflammatory drugs (NSAIDs): Combination use increases risk of gastrointestinal bleeding. (7.2)• Warfarin: Combination use increases risk of bleeding. (7.3)------------------------USE IN SPECIFIC POPULATIONS-----------------------Nursing mothers: Discontinue drug or nursing, taking into consideration importance of drug to mother. (8.3)See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.Revised: 2010FULL PRESCRIBING INFORMATION: CONTENTS*WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS1 INDICATIONS AND USAGE1.1 Acute Coronary Syndrome (ACS)1.2 Recent MI, Recent Stroke, or Established Peripheral ArterialDisease2 DOSAGE AND ADMINISTRATION2.1 Acute Coronary Syndrome2.2 Recent MI, Recent Stroke, or Established Peripheral ArterialDisease2.3 CYP2C19 Poor Metabolizers2.4 Use with Proton Pump Inhibitors (PPI)3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS4.1 Active Bleeding4.2 Hypersensitivity5 WARNINGS AND PRECAUTIONS5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19Function5.2 General Risk of Bleeding5.3 Discontinuation of Plavix5.4 Patients with Recent Transient Ischemic Attack (TIA) orStroke5.5 Thrombotic Thrombocytopenic Purpura (TTP)6 ADVERSE REACTIONS6.1 Clinical Studies Experience6.2 Postmarketing Experience7 DRUG INTERACTIONS7.1 CYP2C19 Inhibitors7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)7.3 Warfarin (CYP2C9 Substrates)8 USE IN SPECIFIC POPULATIONS* Sections or subsections omitted from the full prescribing information are not listed.8.1 Pregnancy8.3 Nursing Mothers8.4 Pediatric Use8.5 Geriatric Use8.6 Renal Impairment8.7 Hepatic Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics12.5 Pharmacogenomics13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility14 CLINICAL STUDIES14.1 Acute Coronary Syndrome14.2 Recent Myocardial Infarction, Recent Stroke, or EstablishedPeripheral Arterial Disease14.3 Lack of Established Benefit of Plavix plus Aspirin in Patientswith Multiple Risk Factors or Established Vascular Disease16 HOW SUPPLIED/STORAGE AND HANDLING17 PATIENT COUNSELING INFORMATION17.1 Benefits and Risks17.2 Bleeding17.3 Other Signs and Symptoms Requiring Medical Attention17.4 Invasive Procedures17.5 Concomitant Medications17.6 Medication GuideFULL PRESCRIBING INFORMATIONWARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERSThe effectiveness of Plavix is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Plavix at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with Plavix at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage and Administration (2.3)].1 INDICATIONS AND USAGE1.1 Acute Coronary Syndrome (ACS)• For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown todecrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.• For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death,re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown.The optimal duration of Plavix therapy in ACS is unknown.1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial DiseaseFor patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.2 DOSAGE AND ADMINISTRATION2.1 Acute Coronary SyndromePlavix can be administered with or without food [see Clinical Pharmacology (12.3)].• For patients with non-ST-elevation ACS (UA/NSTEMI), initiate Plavix with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiate aspirin (75-325 mg once daily) and continue in combination with Plavix [see Clinical Studies (14.1)].• For patients with STEMI, the recommended dose of Plavix is 75 mg once daily orally, administered in combination with aspirin (75-325 mg once daily), with or withoutthrombolytics. Plavix may be initiated with or without a loading dose [see Clinical Studies(14.1)].2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial DiseaseThe recommended daily dose of Plavix is 75 mg once daily orally, with or without food [see Clinical Pharmacology (12.3)].2.3 CYP2C19 Poor MetabolizersCYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established.2.4 Use with Proton Pump Inhibitors (PPI)Omeprazole, a moderate CYP2C19 inhibitor, reduces the pharmacological activity of Plavix. Avoid using omeprazole concomitantly or 12 hours apart with Plavix. Consider using another acid-reducing agent with less CYP2C19 inhibitory activity. A higher dose regimen of clopidogrel concomitantly administered with omeprazole increases antiplatelet response; an appropriate dose regimen has not been established [see Warnings and Precautions (5.1), Drug Interactions (7.1) and Clinical Pharmacology (12.5)].3 DOSAGE FORMS AND STRENGTHS• 75 mg tablets: Pink, round, biconvex, film-coated tablets debossed with “75” on one side and “1171” on the other• 300 mg tablets: Pink, oblong, film-coated tablets debossed with “300” on one side and “1332” on the other4 CONTRAINDICATIONS4.1 Active BleedingPlavix is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.4.2 HypersensitivityPlavix is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product [see Adverse Reactions (6.2)].5 WARNINGS AND PRECAUTIONS5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 FunctionClopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19. Avoid concomitant use of Plavix and strong or moderate CYP2C19 inhibitors.Omeprazole, a moderate CYP2C19 inhibitor, has been shown to reduce the pharmacological activity of Plavix if given concomitantly or if given 12 hours apart. Consider using anotheracid-reducing agent with less CYP2C19 inhibitory activity. Pantoprazole, a weak CYP2C19 inhibitor, had less effect on the pharmacological activity of Plavix than omeprazole [see Drug Interactions (7.1) and Dosage and Administration (2.4)].5.2 General Risk of BleedingThienopyridines, including Plavix, increase the risk of bleeding. If a patient is to undergo surgery and an antiplatelet effect is not desired, discontinue Plavix five days prior to surgery. In patients who stopped therapy more than five days prior to CABG the rates of major bleeding were similar (event rate 4.4% Plavix + aspirin; 5.3% placebo + aspirin). In patients who remained on therapy within five days of CABG, the major bleeding rate was 9.6% for Plavix + aspirin, and 6.3% for placebo + aspirin.Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7-10 days), so withholding a dose will not be useful in managing a bleeding event or the risk of bleeding associated with an invasive procedure. Because the half-life of clopidogrel’s active metabolite is short, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.5.3 Discontinuation of PlavixAvoid lapses in therapy, and if Plavix must be temporarily discontinued, restart as soon as possible. Premature discontinuation of Plavix may increase the risk of cardiovascular events. 5.4 Patients with Recent Transient Ischemic Attack (TIA) or StrokeIn patients with recent TIA or stroke who are at high risk for recurrent ischemic events, the combination of aspirin and Plavix has not been shown to be more effective than Plavix alone, but the combination has been shown to increase major bleeding.5.5 Thrombotic Thrombocytopenic Purpura (TTP)TTP, sometimes fatal, has been reported following use of Plavix, sometimes after a short exposure (<2 weeks). TTP is a serious condition that requires urgent treatment including plasmapheresis (plasma exchange). It is characterized by thrombocytopenia, microangiopathic hemolytic anemia (schistocytes [fragmented RBCs] seen on peripheral smear), neurological findings, renal dysfunction, and fever [see Adverse Reactions (6.2)].6 ADVERSE REACTIONSThe following serious adverse reactions are discussed below and elsewhere in the labeling: • Bleeding [see Warnings and Precautions (5.2)]• Thrombotic thrombocytopenic purpura [see Warnings and Precautions (5.5)]6.1 Clinical Studies ExperienceBecause clinical trials are conducted under widely varying conditions and durations of follow up, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Plavix has been evaluated for safety in more than 54,000 patients, including over 21,000 patientstreated for 1 year or more. The clinically important adverse reactions observed in trialscomparing Plavix plus aspirin to placebo plus aspirin and trials comparing Plavix alone to aspirinalone are discussed below.BleedingCUREIn CURE, Plavix use with aspirin was associated with an increase in major bleeding (primarilygastrointestinal and at puncture sites) compared to placebo with aspirin (see Table 1). Theincidence of intracranial hemorrhage (0.1%) and fatal bleeding (0.2%) were the same in bothgroups. Other bleeding events that were reported more frequently in the clopidogrel group wereepistaxis, hematuria, and bruise.The overall incidence of bleeding is described in Table 1.Table 1: CURE Incidence of Bleeding Complications (% patients)PlaceboEvent Plavix(+ aspirin)* (+ aspirin)*(n=6259)(n=6303)§Major bleeding † 3.7 ‡ 2.7Life-threatening bleeding 2.2 1.8Fatal 0.2 0.25 g/dL hemoglobin drop 0.9 0.9Requiring surgical intervention 0.7 0.7strokes 0.1 0.1HemorrhagicRequiringinotropes 0.5 0.5Requiring transfusion (≥4 units) 1.2 1.0Other major bleeding 1.6 1.0disabling 0.4 0.3SignificantlyIntraocular bleeding with 0.05 0.03significant loss of visionRequiring 2-3 units of blood 1.3 0.9Minor bleeding ¶ 5.1 2.4* Other standard therapies were used as appropriate.† Life-threatening and other major bleeding.‡ Major bleeding event rate for Plavix + aspirin was dose-dependent on aspirin: <100 mg = 2.6%;100-200 mg = 3.5%; >200 mg = 4.9%Major bleeding event rates for Plavix + aspirin by age were: <65 years = 2.5%, ≥65 to <75 years= 4.1%, ≥75 years = 5.9%§ Major bleeding event rate for placebo + aspirin was dose-dependent on aspirin: <100 mg = 2.0%;100-200 mg = 2.3%; >200 mg = 4.0%Major bleeding event rates for placebo + aspirin by age were: <65 years = 2.1%, ≥65 to <75 years =3.1%, ≥75 years = 3.6%¶ Led to interruption of study medication.Ninety-two percent (92%) of the patients in the CURE study received heparin or low molecularweight heparin (LMWH), and the rate of bleeding in these patients was similar to the overallresults.COMMITIn COMMIT, similar rates of major bleeding were observed in the Plavix and placebo groups, both of which also received aspirin (see Table 2).Table 2: Incidence of Bleeding Events in COMMIT (% patients)Type of bleeding Plavix(+ aspirin)(n=22961)Placebo(+ aspirin)(n=22891)p-valueMajor* noncerebral or cerebral bleeding** Major noncerebralFatalHemorrhagic strokeFatal 0.60.40.20.20.20.50.30.20.20.20.590.480.900.910.81Other noncerebral bleeding (non-major) 3.6 3.1 0.005 Any noncerebral bleeding 3.9 3.4 0.004* Major bleeds were cerebral bleeds or non-cerebral bleeds thought to have caused death or that required transfusion.** The relative rate of major noncerebral or cerebral bleeding was independent of age. Event rates for Plavix + aspirin by age were: <60 years = 0.3%, ≥60 to <70 years = 0.7%, ≥70 years = 0.8%. Event rates for placebo + aspirin by age were: <60 years = 0.4%, ≥60 to <70 years = 0.6%, ≥70 years = 0.7%.CAPRIE (Plavix vs. Aspirin)In CAPRIE, gastrointestinal hemorrhage occurred at a rate of 2.0% in those taking Plavix vs.2.7% in those taking aspirin; bleeding requiring hospitalization occurred in 0.7% and 1.1%, respectively. The incidence of intracranial hemorrhage was 0.4% for Plavix compared to 0.5%for aspirin.Other bleeding events that were reported more frequently in the Plavix group were epistaxis and hematoma.Other Adverse EventsIn CURE and CHARISMA, which compared Plavix plus aspirin to aspirin alone, there was no differencein the rate of adverse events (other than bleeding) between Plavix and placebo.In CAPRIE, which compared Plavix to aspirin, pruritus was more frequently reported in those taking Plavix. No other difference in the rate of adverse events (other than bleeding) was reported.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of Plavix.Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.• Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia/pancytopenia, thrombotic thrombocytopenic purpura (TTP)• Eye disorders: Eye (conjunctival, ocular, retinal) bleeding• Gastrointestinal disorders: Gastrointestinal and retroperitoneal hemorrhage with fatal outcome, colitis (including ulcerative or lymphocytic colitis), pancreatitis, stomatitis,gastric/duodenal ulcer, diarrhea• General disorders and administration site condition: Fever, hemorrhage of operative wound• Hepato-biliary disorders: Acute liver failure, hepatitis (non-infectious), abnormal liver function test• Immune system disorders: Hypersensitivity reactions, anaphylactoid reactions, serum sickness• Musculoskeletal, connective tissue and bone disorders: Musculoskeletal bleeding, myalgia, arthralgia, arthritis• Nervous system disorders: Taste disorders, fatal intracranial bleeding, headache• Psychiatric disorders: Confusion, hallucinations• Respiratory, thoracic and mediastinal disorders: Bronchospasm, interstitial pneumonitis, respiratory tract bleeding• Renal and urinary disorders: Increased creatinine levels• Skin and subcutaneous tissue disorders: Maculopapular or erythematous rash, urticaria, bullous dermatitis, eczema, toxic epidermal necrolysis, Stevens-Johnson syndrome,angioedema, erythema multiforme, skin bleeding, lichen planus, generalized pruritus • Vascular disorders: Vasculitis, hypotension7 DRUG INTERACTIONS7.1 CYP2C19 InhibitorsClopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see Warnings and Precautions (5.1) and Dosage and Administration (2.4)].Proton Pump Inhibitors (PPI)A study was conducted with Plavix (300 mg loading dose followed by 75 mg/day) administered with a high dose (80 mg/day) of omeprazole. As shown in Table 3 below, with concomitant dosing of omeprazole, exposure (C max and AUC) to the clopidogrel active metabolite and platelet inhibition were substantially reduced. Similar reductions in exposure to the clopidogrel active metabolite and platelet inhibition were observed when Plavix and omeprazole were administered 12 hours apart (data not shown).There are no adequate studies of a lower dose of omeprazole or a higher dose of Plavix in comparison with the approved dose of Plavix.A study was conducted using Plavix (300 mg loading dose followed by 75 mg/day) and a high dose (80 mg/day) of pantoprazole, a PPI with less CYP2C19 inhibitory activity than omeprazole. The plasma concentrations of the clopidogrel active metabolite and the degree of platelet inhibition were less than observed with Plavix alone but were greater than observed when omeprazole 80 mg was co-administered with 300 mg loading dose followed by 75 mg/day of Plavix (Table 3).Table 3: Comparison of Clopidogrel Active Metabolite Exposure and Platelet Inhibition with and without Proton Pump Inhibitors, Omeprazole and Pantoprazole% Change from Plavix (300 mg/75 mg) alone Plavix plus C max (ng/mL) AUC Platelet Inhibition† (%)Day 1 Day 5 Day 1 Day 5** Day 1 Day 5 Omeprazole* 80 mg ↓46% ↓42% ↓45% ↓40% ↓39% ↓21% Pantoprazole 80 mg ↓24% ↓28% ↓20% ↓14% ↓15% ↓11% †Inhibition of platelet aggregation with 5 mcM ADP*Similar results seen when Plavix and omeprazole were administered 12 hours apart.**AUC at Day 5 is AUC0-247.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)Coadministration of Plavix and NSAIDs increases the risk of gastrointestinal bleeding.7.3 Warfarin (CYP2C9 Substrates)Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis.However, at high concentrations in vitr o, clopidogrel inhibits CYP2C9.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Category BReproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose, respectively, on a mg/m2 basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of a human response, Plavix should be used during pregnancy only if clearly needed.8.3 Nursing MothersStudies in rats have shown that clopidogrel and/or its metabolites are excreted in the milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from clopidogrel, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.8.4 Pediatric UseSafety and effectiveness in the pediatric population have not been established.8.5 Geriatric UseOf the total number of subjects in the CAPRIE and CURE controlled clinical studies, approximately 50% of patients treated with Plavix were 65 years of age and older, and 15% were 75 years and older. In COMMIT, approximately 58% of the patients treated with Plavix were 60 years and older, 26% of whom were 70 years and older.The observed risk of bleeding events with Plavix plus aspirin versus placebo plus aspirin by age category is provided in Table 1 and Table 2 for the CURE and COMMIT trials, respectively [see Adverse Reactions (6.1)]. No dosage adjustment is necessary in elderly patients.8.6 Renal ImpairmentExperience is limited in patients with severe and moderate renal impairment [see Clinical Pharmacology (12.2)].8.7 Hepatic ImpairmentNo dosage adjustment is necessary in patients with hepatic impairment [see Clinical Pharmacology (12.2)].10 OVERDOSAGEPlatelet inhibition by Plavix is irreversible and will last for the life of the platelet. Overdose following clopidogrel administration may result in bleeding complications. A single oral dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and to rats and at 3000 mg/kg to baboons. Symptoms of acute toxicity were vomiting, prostration, difficult breathing, and gastrointestinal hemorrhage in animals.Based on biological plausibility, platelet transfusion may restore clotting ability.11 DESCRIPTIONPlavix (clopidogrel bisulfate) is a thienopyridine class inhibitor of P2Y12 ADP platelet receptors. Chemically it is methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate sulfate (1:1). The empirical formula of clopidogrel bisulfate is C16H16ClNO2S•H2SO4 and its molecular weight is 419.9.The structural formula is as follows:Clopidogrel bisulfate is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56°.Plavix for oral administration is provided as either pink, round, biconvex, debossed, film-coated tablets containing 97.875 mg of clopidogrel bisulfate which is the molar equivalent of 75 mg of clopidogrel base or pink, oblong, debossed film-coated tablets containing 391.5 mg of clopidogrel bisulfate which is the molar equivalent of 300 mg of clopidogrel base.Each tablet contains hydrogenated castor oil, hydroxypropylcellulose, mannitol, microcrystalline cellulose and polyethylene glycol 6000 as inactive ingredients. The pink film coating contains ferric oxide, hypromellose 2910, lactose monohydrate, titanium dioxide and triacetin. The tablets are polished with Carnauba wax.12 CLINICAL PHARMACOLOGY12.1 Mechanism of ActionClopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.12.2 PharmacodynamicsClopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequentADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix. Repeated doses of 75 mg Plavix per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg Plavix per day was between 40% and 60%. Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days.Geriatric PatientsElderly (≥75 years) and young healthy subjects had similar effects on platelet aggregation. Renally-Impaired PatientsAfter repeated doses of 75 mg Plavix per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation.。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
波立维说明书及用量用法
导读：我根据大家的需要整理了一份关于《波立维说明书及用量用法》的内容，具体内容：波立维适用于有过近期发作的脑中风，心肌梗死和确诊外周动脉疾病的患者。
今天我带你了解一下波立维说明书上究竟写了什么?同时带你一一了解!波立维说明书1、波立维的功能主治...
波立维适用于有过近期发作的脑中风，心肌梗死和确诊外周动脉疾病的患者。
今天我带你了解一下波立维说明书上究竟写了什么?同时带你一一了解!
波立维说明书
1、波立维的功能主治
氯吡格雷用于以下患者的预防动脉粥样硬化血栓形成事件; --心肌梗死患者(从几天到小于35天)、缺血性卒中患者(从7天到小于6个月)或确诊外周动脉性疾病的患者。
--急性冠脉综合症的患者 -非ST段抬高性急性冠脉综合症(包括不稳定性心绞痛或非Q波心肌梗死),包括经皮冠状动脉介入术后置入支架的患者与阿司匹林合用。
-用于ST段抬高性急性冠脉综合症患者,与阿司匹林联合,可合并在溶栓治疗中使用。
2、波立维的禁忌
2.1、对药品或本品任一成份过敏。
2.2、严重的肝脏损伤。
2.3、活动性病理性出血,如消化性溃疡或颅内出血。
2.4、哺乳(参见妊娠和哺乳)。
3、波立维的药物相互作用
阿斯匹林:本品增加阿斯匹林对胶原引起的血小板聚集的抑制效果,长期合并用药的安全性无进一步的研究资料。
肝素:健康志愿者研究表明,本品与肝素无相互作用。
但合并用药时应小心。
非甾体抗炎药(NSAIDs):健康志愿者同时服用本品和萘普生,胃肠潜血损失增加,故本品与NSAIDs合用时应小心。
法华令:无合并用药的安全性研究。
4、波立维的药理作用
本品为血小板聚集抑制剂,能选择性地抑制ADP与血小板受体的结合,随后抑制激活ADP与糖蛋白GPⅡb/Ⅲa复合物,从而抑制血小板的聚集。
本品也可抑制非ADP引起的血小板聚集,不影响磷酸二酯酶的活性。
本品通过不可逆地改变血小板ADP受体,使血小板的寿命受到影响。
波立维的用法用量
成人和老年人: 通常推荐成人75mg1日1次口服给药,但根据年龄、体重、症状可50mg1日1次口服给药,与或不与食物同服。
对于急性冠脉综合征的患者: -非ST段抬高性急性冠脉综合征(不稳定性心绞痛或非Q波心肌梗死)患者,应以单次负荷量氯吡格雷300mg开始,然后以75mg每日1次连续服药(合用阿司匹林75mg-325mg/日)。
由于服用较高剂量的阿司匹林有较高的出血危险性,故推荐阿司匹林的剂量不应超过100mg。
最佳疗程尚未正式确定。
临床试验资料支持用药12个月,用药3个月后
表现出最大效果。
-ST段抬高性急性心肌梗死:应以单次负荷量氯吡格雷300mg开始,然后以75mg每日1次,合用阿司匹林,可合用或不合用溶栓剂。
对于年龄超过75岁的患者,不使用氯吡格雷负荷剂量。
在症状出现后应尽早开始联合治疗,并至少用药4周。
目前还没有研究对联合使用氯吡格雷和阿司匹林超过4周后的获益进行确证。
波立维的注意事项
1、不稳定型心绞痛、经皮穿刺冠状动脉内支架安置术、冠状动脉旁路移植术等;急性缺血性脑卒中(发病时间少于7天);由于创伤、手术或其他病理原因而可能引起出血增多以及有伤口(特别是在胃肠道和眼内)易出
血的患者;服用易出现胃肠道损伤药物(如非甾体解热镇痛药)的患者;肾
功能损害者;孕妇及哺乳期妇女。
2、择期手术患者可在术前1周停止使用波立维。
3、波立维无专用的解毒药。
如果需要迅速恢复正常的出血时间,可进行血小板输注以拮抗波立维的药理作用。
4、药物对老人的影响:老年人在血浆中主要代谢物浓度明显高于年轻健康志愿者,但较高的血浆浓度与血小板聚集及出血时间的差异无关,故没
有必要对老年人调整剂量。
5、用药前后及用药时应当检查或监测白细胞和血小板计数。